In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Righting Wright Medical

Executive Summary

In the early 90's, already strong in total knee replacements, Wright Medical ambitiously staked out markets in hips, trauma, spine and arthroscopy. Much of the expansion was accomplished through a series of acquisitions, perhaps the most important of which was the 1994 acquisition of Orthomet Inc. But those ambitions were never realized, and Wright spent from 1996 to 1998 changing management several times, laying off large numbers of employees and exiting nearly all of the businesses it tried to get into in 1993-'94, all while sales were flat or in decline. Nevertheless, Warburg Pincus, which bought Wright this month, clearly sees opportunity where others don't.
Advertisement

Related Content

Is Wright Medical Back on Track?
Is Wright Medical Back on Track?
Devices Pique Private Equity's Interest
Devices Pique Private Equity's Interest

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel